Precision Medicine Market growth outlook with industry review and forecasts - PowerPoint PPT Presentation

About This Presentation
Title:

Precision Medicine Market growth outlook with industry review and forecasts

Description:

Precision Medicine Market size was over USD 39 billion in 2015, and is anticipated to grow at 10.5% CAGR from 2016 to 2023. Get more details @ – PowerPoint PPT presentation

Number of Views:146

less

Transcript and Presenter's Notes

Title: Precision Medicine Market growth outlook with industry review and forecasts


1
Precision Medicine Market worth 87.7bn by 2023
Global Market Insights Inc.
Fuel Cell Market size worth 25.5bn by 2024
2
Key Insights from Precision Medicine Market
  • Drug discovery technology contributed over USD 9
    billion to the global precision medicine market
    size in 2015, and is estimated to expand at 8.3
    CAGR from 2016 to 2023. NGS and other such
    technologies will open new opportunities for
    industry participants. Regulation of NGS based
    test development will help create regulatory
    processes for genetic test development and
    application.
  • The global companion diagnostics market is
    predicted to reach USD 17 billion by 2023. It
    plays a significant role in development of
    targeted drugs, thus speeding up the move towards
    more precise and individualized pharmacotherapy.
  • Oncology application was over 30 of the
    precision medicine market share in 2015. There
    have been significant developments taken place
    across the globe in the area of breast cancer and
    other related cancers. Predictive biomarkers in
    lung cancer therapy targets receptors such as
    c-ros oncogene 1 receptor tyrosine kinase (ROS1),
    Epidermal Growth Factor Receptor (EGFR), Immune
    Checkpoints, and Anaplastic Lymphoma Kinase
    (ALK).

3
Continued...
  • U.S. precision medicine market share accounted
    for over 65 of the North American revenue in
    2015, and is anticipated to continue witnessing
    growth due to increased government initiatives.
    For instance, The Presidents budget in 2016 has
    allocated USD 130 million to the NIH for
    development of a national research cohort of a
    million voluntary U.S. participants, and the data
    is linked to EHR for easy access to academic
    scientists and physicians.
  • China contributed 25 to the Asia Pacific
    precision medicine market size in 2015, mainly
    due to considerable government initiatives
    supporting growth in the region. Pfizer,
    Novartis, Covance, Medtronics, Qiagen, Quest
    Diagnostics, Roche Holding, Teva Pharmaceuticals,
    and Biocrates Life Sciences are some notable
    industry participants.

4
Europe precision medicine market size, by
application, 2013 - 2023 (USD Million)

5

Browse Full Market Research Report On Precision
Medicine Market _at_ https//goo.gl/Nr1ZHe Request
for a Sample of this Research Report
_at_ https//www.gminsights.com/request-sample/detail
/671
6
360 Analysis
  • Application Trends
  • Oncology application accounted for over 30 of
    precision medicine market share in 2015 and will
    grow at 10.9 CAGR estimations from 2016 to 2023.
    Oncology is leading the way in utilizing the
    molecular profile of an individual's cancer
    genome to optimize disease management. CNS
    application was valued at over USD 9 billion in
    2015. Neurosciences therapeutics has been using
    the approach for a long time. For instance, the
    success of Deep Brain Stimulation (DBS) product
    provides a classic example for application in
    brain circuitry.
  • Regional Trends
  • U.S. precision medicine market share was 65 of
    the North American revenue in 2015, mainly on
    account of favorable regulatory landscape. The
    Presidents budget has allocated USD 215 million
    to NIH, NCI, and FDA for development of novel
    solutions.
  • Competitive Market Share
  • Key industry players contributing to global
    precision medicine market share include Pfizer,
    Roche, Covance, Novartis, Qiagen, Biocrates Life
    Sciences, Teva Pharmaceutical, Nanostring
    Technologies, Laboratory Corporation of America
    Holdings, Tepnel Pharma Services, Intomics,
    Ferrer InCode, Silicon Biosystems, Eagle
    Genomics, Medtronic, and Quest Diagnostics. Roche
    is developing an integrated genomics portfolio
    for next generation sequencing (NGS).


7
Stay In Touch Website www.gminsights.com Soci
al Media
Write a Comment
User Comments (0)
About PowerShow.com